WO2000022433A1 - Verfahren und verwendung zur markierung und identifizierung applizierter mittel - Google Patents
Verfahren und verwendung zur markierung und identifizierung applizierter mittel Download PDFInfo
- Publication number
- WO2000022433A1 WO2000022433A1 PCT/DE1999/003193 DE9903193W WO0022433A1 WO 2000022433 A1 WO2000022433 A1 WO 2000022433A1 DE 9903193 W DE9903193 W DE 9903193W WO 0022433 A1 WO0022433 A1 WO 0022433A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immunogen
- organism
- use according
- detection
- agent
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
Definitions
- the invention relates to a method and a use for the marking and identification of applied agents.
- a method for the internal marking of substances is known from US Pat. No. 5,139,812. In principle, such a method is also suitable for marking packaging. However, the production of such marked packaging is complex. Such proof of origin can be avoided by filling the marked packaging several times.
- the object of the invention is to provide a method and a use with which the disadvantages of the prior art are eliminated.
- a method and a use for the marking and identification of applied agents, such as medicines, vaccines, blood supplies and the like, are to be specified which are easy to use, counterfeit-proof and harmless to the organism.
- the proposed method enables the means provided for application to be marked in a simple manner.
- the marking is harmless to the organism. It is easy to identify.
- a protein and / or peptide is used as the immunogen, which usually does not enter the organism either as an agent to be administered or via the food chain and against which no antibodies are naturally present before the application.
- the protein or peptide can expediently be used as a hapten in combination with a carrier.
- Such immunogens are harmless to the organism; they are easy and clearly verifiable.
- the immunogen is advantageously designed such that the antibodies or T cells formed or their receptors remain permanently in the organism. So even after length other periods are checked whether an agent of a certain origin has been applied.
- the agent can be provided with a mixture of several immunogens. This enables coding of the marking so that a large number of different means can be marked individually.
- the agent instead of the immunogen with a deoxyribonucleic acid (DNA) coding therefor and a corresponding regulatory sequence.
- DNA deoxyribonucleic acid
- ELISA, EIA and / or RIA are expediently used as the enzyme immunological or immunochemical detection method.
- Test sticks can be used. Such detection methods are particularly easy to carry out.
- an adjuvant can also be applied together with the agent.
- the application is usually carried out by injection, infusion or in the case of vaccines e.g. with vaccination guns.
- the enzyme immunological or immunochemical detection methods already mentioned can be used as the method for detecting the immunogen.
- immunogens such as "keyhole limpet hemocyanin", "green fluorescent protein” from Aequoria victoria, inactive snake toxins and virus proteins can be administered together with a blood preserve.
- the aforementioned hemocyanin is hemocyanin from the marine gastropod "Megathura cremulata”.
- naturally occurring peptides or polypeptides such as hirudin, pheromonotropin or ranalexin can also be applied.
- synthetically produced fragments of partial amino acid sequences of naturally occurring immunogens can also be used for biomarking.
- artificial proteins and peptides can also serve as immunogens, the amino acid sequence of which does not correspond to any previously known substance, but which are assembled or produced exclusively for the purpose of biomarking and which are wholly or partly composed of non-standard amino acids, such as modified amino acids, D Amino acids or other chemically synthetic amino acids and derivatives derived therefrom can exist.
- a DNA can also be applied which has a nucleotide sequence coding for the immunogen.
- the DNA can contain partial sequences or the entire keyhole limpet hemocyanin gene. However, it can also be designed such that it only describes a short peptide, where several immunogens can be encoded on a single DNA.
- both cDNA and genomic DNA with intron sequences can be applied.
- the DNA can contain further sequences which are important for the expression and processing of the immunogen in the organism. These are promoter sequences and sequences which bring about transcription termination and polyadenylation of the mRNA and intracellular trafficking of the immunogen.
- Suitable expression regulators are promoters which ensure a high transcription rate of the DNA, for example the "immediate early" promoter of the cytomegalovirus or the promoter of a farm animal-specific "house-keeping" gene such as ⁇ -actin.
- promoters are also suitable which specifically limit the expression of the immunogen to predetermined body cells.
- the polypeptide formed can be directed into the lumen of the endoplasmic reticulum and directed into cellular distribution channels for secretion or expression and presentation on the cell surface.
- the antibodies induced by the substances mentioned are detected by conventional detection methods such as ELISA, EIA and RIA, immunoblot, immunodiffusion or immunofluorescence, preferably using test sticks which e.g. be immersed in a blood sample taken.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000576280A JP2002527749A (ja) | 1998-10-13 | 1999-10-04 | 既投与作用物質を標識および特定するための方法および使用 |
EP99970471A EP1127276A1 (de) | 1998-10-13 | 1999-10-04 | Verfahren und verwendung zur markierung und identifizierung applizierter mittel |
CA002343789A CA2343789A1 (en) | 1998-10-13 | 1999-10-04 | Procedure and use for the labeling and identification of administered agents |
NO20011259A NO20011259D0 (no) | 1998-10-13 | 2001-03-13 | FremgangsmÕte og anvendelse for merking og identifisering av anvendte substanser |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1998147118 DE19847118C2 (de) | 1998-10-13 | 1998-10-13 | Verfahren und Verwendung zur Markierung und Identifizierung applizierter Mittel |
DE19847118.1 | 1998-10-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000022433A1 true WO2000022433A1 (de) | 2000-04-20 |
Family
ID=7884294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1999/003193 WO2000022433A1 (de) | 1998-10-13 | 1999-10-04 | Verfahren und verwendung zur markierung und identifizierung applizierter mittel |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1127276A1 (de) |
JP (1) | JP2002527749A (de) |
CA (1) | CA2343789A1 (de) |
DE (1) | DE19847118C2 (de) |
NO (1) | NO20011259D0 (de) |
WO (1) | WO2000022433A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004073738A2 (de) * | 2003-02-18 | 2004-09-02 | Responsif Gmbh | Zusammensetzung zur verabreichung an ein lebewesen und verfahren zur markierung von mittlen |
EP1581256A2 (de) * | 2002-11-14 | 2005-10-05 | Pfizer Products Inc. | Verwendung von rmlt als marker-antigen für vakzine und als synergistisches adjuvans mit amphigen |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998018003A2 (de) * | 1996-10-23 | 1998-04-30 | Manfred Gareis | Verfahren zum herkunftsnachweis von nutztieren sowie davon stammenden produkten |
WO1999036775A1 (de) * | 1998-01-14 | 1999-07-22 | November Aktiengesellschaft_Gesellschaft Für Molekulare Medizin | Verfahren zum herkunftsnachweis von nutztieren sowie davon stammenden produkten |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5429952A (en) * | 1988-02-02 | 1995-07-04 | Biocode, Inc. | Marking of products to establish identity and source |
FR2649518B1 (fr) * | 1989-07-07 | 1991-10-18 | Bioprobe Systems Sa | Procede et dispositif de marquage crypte de haute securite pour la protection d'objets de valeur |
GB9314394D0 (en) * | 1993-07-12 | 1993-08-25 | Slater James H | A security device using an ultrasensitive microtrace for protecting materials,articles and items |
SE9304211L (sv) * | 1993-12-20 | 1995-06-21 | Joeran Lundh | Identifieringssystem |
-
1998
- 1998-10-13 DE DE1998147118 patent/DE19847118C2/de not_active Expired - Fee Related
-
1999
- 1999-10-04 EP EP99970471A patent/EP1127276A1/de not_active Withdrawn
- 1999-10-04 WO PCT/DE1999/003193 patent/WO2000022433A1/de not_active Application Discontinuation
- 1999-10-04 JP JP2000576280A patent/JP2002527749A/ja active Pending
- 1999-10-04 CA CA002343789A patent/CA2343789A1/en not_active Abandoned
-
2001
- 2001-03-13 NO NO20011259A patent/NO20011259D0/no not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998018003A2 (de) * | 1996-10-23 | 1998-04-30 | Manfred Gareis | Verfahren zum herkunftsnachweis von nutztieren sowie davon stammenden produkten |
WO1999036775A1 (de) * | 1998-01-14 | 1999-07-22 | November Aktiengesellschaft_Gesellschaft Für Molekulare Medizin | Verfahren zum herkunftsnachweis von nutztieren sowie davon stammenden produkten |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1581256A2 (de) * | 2002-11-14 | 2005-10-05 | Pfizer Products Inc. | Verwendung von rmlt als marker-antigen für vakzine und als synergistisches adjuvans mit amphigen |
EP1581256A4 (de) * | 2002-11-14 | 2006-06-07 | Pfizer Prod Inc | Verwendung von rmlt als marker-antigen für vakzine und als synergistisches adjuvans mit amphigen |
WO2004073738A2 (de) * | 2003-02-18 | 2004-09-02 | Responsif Gmbh | Zusammensetzung zur verabreichung an ein lebewesen und verfahren zur markierung von mittlen |
WO2004073738A3 (de) * | 2003-02-18 | 2004-10-28 | Responsif Gmbh | Zusammensetzung zur verabreichung an ein lebewesen und verfahren zur markierung von mittlen |
Also Published As
Publication number | Publication date |
---|---|
NO20011259L (no) | 2001-03-13 |
CA2343789A1 (en) | 2000-04-20 |
NO20011259D0 (no) | 2001-03-13 |
DE19847118A1 (de) | 2000-05-04 |
DE19847118C2 (de) | 2000-09-07 |
EP1127276A1 (de) | 2001-08-29 |
JP2002527749A (ja) | 2002-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cole et al. | Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striatum | |
DE69433090T2 (de) | Conotoxine, die an den acetylcholinrezeptor anbinden | |
Rostène et al. | Neurotensin and neuroendocrine regulation | |
DE69736712T2 (de) | Verfahren zur milderung von neuropatischen schmerz mit prosaposin verwandten peptiden | |
Quirion et al. | Evidence for an endogenous peptide ligand for the phencyclidine receptor | |
DE19964269B4 (de) | Verfahren zur Detektion des Proliferationspotentials von Zellen | |
Chang et al. | Interleukin-1 activation of FOS proto-oncogene protein in the rat hypothalamus | |
WO1999036568A2 (de) | Verfahren zum identifizieren von t-zell-stimulierenden proteinfragmenten | |
Inagaki et al. | Distribution of enkephalin-immunoreactive neurons in the forebrain and upper brainstem of the squirrel monkey | |
EP1353948B1 (de) | Lösliche cyclische analoga des beta amyloiden peptids | |
EP3346273A1 (de) | Neue, von d3 agbeleitete d-enantiomere peptide und deren verwendung | |
DE69732350T2 (de) | Persephin und verwandte wachstumsfaktoren | |
WO2000022433A1 (de) | Verfahren und verwendung zur markierung und identifizierung applizierter mittel | |
DE60124915T2 (de) | Synthetische peptide gegen neurologische krankheiten | |
DE69631516T2 (de) | Familie von Kaliumkanälen von Säugetieren, deren Klonierung und Anwendung für Drogenscreening | |
DE69738302T2 (de) | Neues semaphorin-gen: semaphorin y | |
DE69722809T2 (de) | Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)-antagonisten und inhibitoren der hautmastzell-degranulation | |
CN109844109A (zh) | TATκ-CDKL5融合蛋白、其组合物、配制品以及用途 | |
Woolley | Convenient method for assay in vivo of antimetabolites of serotonin | |
Schmidt | Changes in subcellular distribution of ependymins in goldfish brain induced by learning | |
DE60126602T2 (de) | Neue collectine | |
Davis et al. | Memory enhancement induced in chicks by L-prolyl-L-leucyl-glycineamide | |
Krowicki et al. | Hindbrain effects of PACAP on gastric motor function in the rat | |
WO1999036775A1 (de) | Verfahren zum herkunftsnachweis von nutztieren sowie davon stammenden produkten | |
EP0984986A2 (de) | Das protein des humanen ryanodinrezeptors vom typ 3 sowie dafür kodierende dna-moleküle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 15460 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2343789 Country of ref document: CA Ref country code: CA Ref document number: 2343789 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 576280 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999970471 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09807346 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999970471 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999970471 Country of ref document: EP |